

References

I-24

1. Nulojix (belatacept) for intravenous administration [package insert]. Bristol-Myers Squibb. Princeton, NJ, 06/2011. Revised 4/2018.
2. Brakemeier S, Kannenkeril, Durr M, et al. Experience with belatacept rescue therapy in kidney transplant recipients. *Transpl Int*. 2016;29:1184-1195.
3. Wojciechowski D, Chandran S, Yang JYC, et al. Retrospective evaluation of the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: A single-center clinical experience. *Clin Transplant*. 2017;31:e13042.
4. Woodle ES, Kaufman DB, Shields AR, et.al. BEST Study Group. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial. *Am J Transplant*. 2020;20(4):1039-1055.
5. Grinyó JM, Del Carmen Rial M, Alberu J, et. al. Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: Results from a phase 2 randomized trial. *Am J Kidney Dis*. 2017;69(5):587-594.
6. Kumar J, Reccia I, Viridis F, et. al. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review. *World J Transplant*. 2021; 11(3); 70-86.
7. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Belatacept.
8. Micromedex DrugDex Compendium®. 2021. Belatacept (Nulojix)
9. Belatacept In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 6/24/2021.